Search Results - immunotherapy

124 Results Sort By:
New Lipiodol Formulation for Treating Hepatocellular Carcinoma with Transarterial Chemoimmunoembolization
NU 2021-148 INVENTORS Dong Hyun Kim* Heegon Kim SHORT DESCRIPTION A new Lipiodol formulation designed to improve the efficacy and safety of transarterial chemoembolization in combination with immunotherapy. BACKGROUND Transarterial chemoembolization...
Published: 9/4/2024   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Drug delivery, Gastrointestinal and Hepatic disease, Immunotherapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Affinity and Functional Based Screening of T Cell Receptor Repertoire Using Nanovials (Case No. 2024-042)
Summary: Researchers in the Department of Bioengineering at UCLA have developed a hydrogel platform that measures single T cell secretions, aiding in the definition of T cell receptor repertoires for functional immunotherapy applications. Background: T cell immunotherapies, namely T cell receptor (TCR) therapies, have emerged as promising candidates...
Published: 9/20/2024   |   Inventor(s): Dino Di Carlo, Owen Witte, Doyeon Koo, Zhiyuan Mao
Keywords(s): Cancer Immunotherapy, CAR-T cell therapy, Flow Cytometry, hydrogel, Immunooncology, Immunotherapy, Peptide, single cell analysis, T Cell, T cell based therapy
Category(s): Diagnostic Markers > Immunology, Life Science Research Tools > Screening Libraries, Therapeutics > Immunology And Immunotherapy
Methods and Compositions for Treating Melanoma (UCLA Case No. 2021-324)
The Graeber Laboratory at UCLA discovered a novel mechanism for treating melanoma using ferroptosis, a type of programmed cell death, that shows promise against therapy resistance. BACKGROUND: Melanoma is a highly aggressive skin cancer that spreads throughout the body and can be fatal if left untreated. Therapies for melanoma range from immunotherapy...
Published: 7/10/2024   |   Inventor(s): Thomas Graeber
Keywords(s): Cancer, ferroptosis, Immunotherapy, MAPK signaling, Melanoma, Oncology, Skin, tumor resistance
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Engineered T Cells Capable of Simultaneous Tumor Targeting and Alteration of Tumor Microenvironment Through Vasculature Normalization (UCLA Case No. 2023-264)
UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have built a series of chimeric antigen receptor (CAR)-T cells that target different antigens and secrete different anti-angiogenic proteins. Additionally, researchers also constructed bispecific CARs that respond to tumor antigen and pro-angiogenic molecules. BACKGROUND:...
Published: 6/27/2024   |   Inventor(s): Yvonne Chen
Keywords(s): Cancer, Cancer Immunotherapy, CAR-T cell therapy, immunosuppression, Immunosuppressive Drug, Immunotherapy, solid tumors, Tumor microenvironment, tumor vasculature, VEGF
Category(s): Therapeutics > Oncology
Targeting Serotonin Transporter (SERT) for Cancer Immunotherapy (UCLA Case No. 2024-204)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have unveiled a novel therapeutic strategy utilizing SSRIs for solid cancer immunotherapy. BACKGROUND: Immunotherapy has become a highly effective method to combat cancer that enhances a patient’s immune system to attack tumors with high specificity. For instance,...
Published: 6/18/2024   |   Inventor(s): Lili Yang
Keywords(s): Cancer, Immune checkpoint blockade, immune checkpoint inhibitors, Immunotherapy, selective serotonin reuptake inhibitors (SSRIs), serotonin, solid tumors, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Immune Modulator Encoded Lipid Nanoparticle Formulation Improves T Cell Response to Vaccines
Researchers developed an LNP-mRNA-based vaccine that encodes different cytokine mRNAs, as a method to enhance CD8+ T cell responses and memory formation. Problem: Lipid nanoparticles (LNPs) are an emerging technique to deliver mRNA in vivo more efficiently. While recent progress in mRNA technology has allowed the rapid development of SARS-COV2 vaccines,...
Published: 7/2/2024   |   Inventor(s): Christopher Hunter, Drew Weissman, Mohamad Alameh, Emily Aunins, Anthony Phan
Keywords(s): Bioengineering, Drug Delivery, Immunology, Immunoncology, Immunotherapy, Infectious Disease, Nanotechnology
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Vaccines
Strategies to Detect, Prevent and Reverse Acquired Resistance to Immune Checkpoint Blockade Therapy (UCLA Case No. 2024-085)
UCLA researchers in the Department of Medicine have uncovered novel mechanism of acquired resistance against immune checkpoint blockade therapy in melanoma patients. BACKGROUND: Immune checkpoint blockade (ICB) therapy is a type of cancer immunotherapy that targets immune system components in order to reactivate immune cells to combat tumor cells....
Published: 5/8/2024   |   Inventor(s): Roger Lo
Keywords(s): acquired resistance, Apoptosis, Cancer, Cancer Immunotherapy, Immune checkpoint blockade, Immunotherapy, Melanoma, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Novel Anti-mesothelin CAR for Use in Engineered Cell Therapies (UCLA Case No. 2023-281)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have developed a nanobody-based CAR T cell platform with increased stability and cross-immunogenicity between human and mouse antigens. BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy makes use of reengineered T cells to target and clear cancer cells....
Published: 6/28/2024   |   Inventor(s): Yvonne Chen
Keywords(s): Cancer, CAR-T cell platform, CAR-T cell therapy, cell engineering, Immunotherapy, Mesothelin, nanobody, Nanoparticle
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Targeted Delivery of IFN-gamma Using Antibody Fusion Proteins (UCLA Case No. 2017-543)
UCLA researchers in the Departments of Microbiology, Immunology & Molecular Genetics (MIMG) and Medicine have developed antibody–cytokine fusion proteins that enable the targeted delivery of active interferon-gamma (IFNγ) for cancer treatment. Interferon-gamma (IFNγ), a type II interferon, is a cytokine released by both natural...
Published: 2/26/2024   |   Inventor(s): Sherie Morrison, John Timmerman, Kham (Ryan) Trinh
Keywords(s): Antibody Delivery Platforms, Drug Delivery, Immunotherapy, Life Science Research Tools, Therapeutics & Vaccines
Category(s): Therapeutics, Platforms > Drug Delivery, Platforms > Drug Delivery > Antibody Delivery Platforms, Life Science Research Tools, Therapeutics > Immunology And Immunotherapy
New Fusion Molecule Based on Novel TAA Variant (UCLA Case No. 2007-217)
BACKGROUND: Renal cell carcinoma (RCC) affects approximately 39,000 Americans and causes an estimated 13,000 deaths per year. Metastatic RCC poses a therapeutic challenge because of its resistance to conventional modes of therapy. Approximately one third of RCC patients will present at the metastatic stage and one third of patients with localized disease...
Published: 2/16/2024   |   Inventor(s): Arie Belldegrun, Zhenhua Li
Keywords(s): Cancer, Immunotherapy, Renal, Renal cell carcinoma, renal diseases
Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Renal
1 2 3 4 5 6 7 8 9 10 ...